June 11 (Reuters) - Sage Therapeutics said on Tuesday its experimental drug met the main goal of a mid-stage study in patients with a type of rare disease known as Huntington's disease. (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)